Abvc Biopharma (ABVC) Operating Leases (2019 - 2026)
Abvc Biopharma's (ABVC) quarterly Operating Leases came in at $1.5 million in Q1 2026, up 804.84% YoY from $166985.0 in Q1 2025, and down 5.61% on a QoQ basis from $1.6 million in Q4 2025.
Abvc Biopharma (ABVC) Operating Leases (2019 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 8 years of Operating Leases data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Operating Leases rose 804.84% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 804.84% YoY) and the FY2025 annual result came in at $1.6 million, up 575.97% from the prior year.
- Operating Leases retreated to $1.5 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $1.6 million in Q4 2025 to a low of $142201.0 in Q3 2024.
- A 5-year average of $596245.1 and a median of $507151.0 in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases slumped 76.42% — and 2026, when it surged 804.84%.
- Tracing ABVC's Operating Leases over 5 years: stood at $791827.0 in 2022, then tumbled by 48.54% to $407457.0 in 2023, then tumbled by 41.88% to $236807.0 in 2024, then jumped by 575.97% to $1.6 million in 2025, then decreased by 5.61% to $1.5 million in 2026.
- The last three Operating Leases figures came in at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $164072.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - |
| 10 | Abvc Biopharma | 24.11 Mn | 24.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 164,072.00 |
| Jun 30, 2025 | 177,133.00 |
| Mar 31, 2025 | 166,985.00 |
| Dec 31, 2024 | 236,807.00 |
| Sep 30, 2024 | 142,201.00 |
| Jun 30, 2024 | 228,802.00 |
| Mar 31, 2024 | 708,022.00 |
| Dec 31, 2023 | 407,457.00 |
| Sep 30, 2023 | 507,151.00 |
| Jun 30, 2023 | 609,140.00 |
| Mar 31, 2023 | 711,427.00 |
| Dec 31, 2022 | 791,827.00 |
| Sep 30, 2022 | 880,178.00 |
| Jun 30, 2022 | 944,266.00 |
| Mar 31, 2022 | 349,008.00 |
| Dec 31, 2021 | 1.12 Mn |
| Sep 30, 2021 | 1.21 Mn |